StreetInsider.com News Articles

Intelligent Bio Solutions starts interference study for FDA drug screening submission

Tue, 16 Jun 2026 08:30:37 -0400

Intelligent Bio Solutions Inc. (NASDAQ: INBS) has initiated an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for codeine detection, according to a press release from the company.

The study will enroll 75 healthy adult participants who will be evaluated under both undosed and dosed conditions while handling substances that could potentially interfere with test results. The protocol includes multiple collection time points, with results confirmed via liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.

The company has partnered again with CenExel Clinical Research, Inc. to conduct the study, which will follow FDA

Intelligent Bio Solutions starts interference study for FDA drug screening submission

Tue, 16 Jun 2026 08:30:37 -0400

The company has partnered again with CenExel Clinical Research, Inc. to conduct the study, which will follow FDA

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Tue, 16 Jun 2026 08:30:00 -0400

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

Company expects to complete the study by mid-July 2026, with plans to include results in its FDA 510(k) submission package, along with data from the concurrent Method Comparison Study

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of an Interference Study to support its FDA 510(k) submission for

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Tue, 16 Jun 2026 08:30:00 -0400

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

Company expects to complete the study by mid-July 2026, with plans to include results in its FDA 510(k) submission package, along with data from the concurrent Method Comparison Study

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Tue, 16 Jun 2026 08:30:00 -0400

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

Company expects to complete the study by mid-July 2026, with plans to include results in its FDA 510(k) submission package, along with data from the concurrent Method Comparison Study

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Tue, 16 Jun 2026 08:30:00 -0400

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

Company expects to complete the study by mid-July 2026, with plans to include results in its FDA 510(k) submission package, along with data from the concurrent Method Comparison Study

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Thu, 04 Jun 2026 08:30:00 -0400

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.

Conference Details
Date: June 16-18, 2026
Location: Bellagio Hotel & Casino, Las Vegas
Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT
Presentation Location: Track 7 – Donatello 3
Registration: Interested investors can register to attend here

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Thu, 04 Jun 2026 08:30:00 -0400

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Thu, 04 Jun 2026 08:30:00 -0400

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Thu, 04 Jun 2026 08:30:00 -0400

Intelligent Bio Solutions begins FDA study for drug screening device

Tue, 02 Jun 2026 08:30:53 -0400

Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced the start of a multi-site method comparison study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for opiate codeine detection.

The company partnered with CenExel Clinical Research, Inc. to conduct the study, which will evaluate the accuracy of the fingerprint-based drug screening system when operated by intended end-users across multiple clinical sites. The study will enroll 135 donor participants randomized into dosing groups with demographics reflecting U.S. population diversity.

Nine operator participants representing typical workplace drug screening personnel will collect and analyze fingerprint sweat specimens. The

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Tue, 02 Jun 2026 08:30:00 -0400

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System

Company expects to complete enrollment and data collection by the end of July, 2026

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine.

The Company

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Tue, 02 Jun 2026 08:30:00 -0400

The Company

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Tue, 02 Jun 2026 08:30:00 -0400

The Company

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Tue, 02 Jun 2026 08:30:00 -0400

The Company

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Wed, 13 May 2026 08:30:00 -0400

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales